Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents [clinicaltrials:NCT00191542]

Bio2RDF uri

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents [clinicaltrials:NCT00191542]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00191542

Bio2RDF identifier

NCT00191542

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00191542

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00191542

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:622caf56b633089ea886f65319748980

brief summary [clinicaltrials_vocabulary:brief-summary]

Comparison of the effec ...... after 10 weeks of treatment

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:21147f649a83f2a876637c37cf0bdad4]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:4ae14ccecd2fa3b7ffd4903a78456372]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:05a7517d2154393838337f74e8ab02d6]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:0625ec05f662e8410512a64236b17004]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:1a08fb0b1eca56421965291128bb47ae]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:3bb686c6399658205b3591ab352a165f]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:415ca24f030b629b74466881cab7f492]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:4ac6f8ebbbb6a12bd8cd1c896b09859c]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:4e235d0ae7ca40d1a31df044e586101c]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:5e1b11ac0c6eedf7eccbfa0a53dd04a6]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:611b044e67d88b91b99f0d01b445ac33]

To test the hypothesis that atomoxetine and psychoeducation given for 10 weeks is superior to placebo and psychoeducation in improving overall [clinicaltrials_resource:675a5918a47c18b380b03ef3b689a9bd]

completion date [clinicaltrials_vocabulary:completion-date]

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00191542 [clinicaltrials_resource:d0df526026b147bde8c79ebbc4a4488d]

enrollment [clinicaltrials_vocabulary:enrollment]

100

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo [clinicaltrials_resource:00936494e316bfc94184f209a4f2ed57]

Atomoxetine [clinicaltrials_resource:db26cef789723349ac526ba267d89f54]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Atomoxetine [clinicaltrials_resource:f6dfb98ca3654af73de96e2cdd47b28a]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2006-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

location [clinicaltrials_vocabulary:location]

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician [clinicaltrials_resource:52c4f1b3b6f7e98ee0a3dfe2a0ae39fb]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00191542

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Randomised, Double Blind Pla ...... edish Children and Adolescents

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

6.671

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:4ec6b5d162a98ea5097869a73fe08479]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Sweden: Medical Products Agency [clinicaltrials_resource:7c21b30b49d2d7f3e344daca0730fae9]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

secondary id [clinicaltrials_vocabulary:secondary-id]

B4Z-SO-LY15

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

start date [clinicaltrials_vocabulary:start-date]

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00191542 study design [clinicaltrials_resource:6b679c1bcb0bed8963d717e9e6ce7892]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00191542

verification date [clinicaltrials_vocabulary:verification-date]

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00191542

http://www.w3.org/2001/XMLSchema#string

title

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Atomoxetine vs Placebo in the ...... s [clinicaltrials:NCT00191542]

@en